A randomized placebo-controlled safety and dose-finding study for the use of the IL-6 inhibitor clazakizumab in patients with life-threatening COVID-19 infection

Brief description of study

The purpose of this research study is to investigate the safety of treatment with an investigational drug called clazakizumab compared to a placebo (inactive substance) in critically ill patients who have been diagnosed with COVID-19 and have signs of respiratory failure. We think this drug might be effective based on the potential benefit of a similar drug in a small number of patients who developed similar life-threatening pulmonary failure after acquiring COVID-19. An investigational drug is one that has not been approved by the regulatory authorities such as the US Food and Drug Administration (FDA). Clazakizumab is an antibody drug (a protein made in yeast) that blocks another protein called interleukin 6 (IL-6) which is important in inflammation.

Clinical Study Identifier: s20-00392
ClinicalTrials.gov Identifier: NCT04343989

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.